A simple sit-to-stand test may predict adverse outcomes, hospitalizations, and death in adults with pulmonary hypertension, a study found.

Can a one-minute sit-to-stand test predict long-term outcomes in pulmonary hypertension? New data suggest it can. Read more.

Researchers have found that a novel blood test can be used to easily evaluate disease severity in patients with pulmonary arterial hypertension (PAH) and predict survivability. PAH is a rare, ...

Pulmonary hypertension is traditionally defined as a mean pulmonary artery pressure of ≥25 mmHg when a patient is at rest, though a mean pressure of >20 mm Hg is considered to be abnormal and may ...

Pulmonary arterial hypertension (PAH) is a type of high blood pressure in the arteries that go from your heart to your lungs. It happens when these arteries become narrow or blocked, making it harder ...

The Chronic Thromboembolic Pulmonary Hypertension (CTEPH) program at Baylor St. Luke’s Medical Center is one of a handful of specialized programs in the country offering expert multidisciplinary care ...

(HealthDay News) — For patients with pulmonary hypertension associated with heart failure and preserved ejection fraction (PH-HFpEF), the 6-minute walk distance (6-MWD) test can independently predict ...

Investigators provide recent information on the classification, pathophysiology, diagnosis, and treatment of pulmonary arterial hypertension, focusing specifically on its impact on women. Pulmonary ...

The 6th World Symposium on Pulmonary Hypertension Task Force on hemodynamic definitions and clinical classifications defined pulmonary hypertension (PH) as a mean pulmonary artery pressure at rest of ...

Winrevair, also known as sotatercept-csrk, is a medicine used to treat pulmonary arterial hypertension (PAH), which causes high blood pressure in the arteries that go from your heart to your lungs.